NCT00041704View on ClinicalTrials.gov

The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

August 31, 2002

Study Completion Date

August 31, 2004

Conditions

Candidiasis

Interventions

DRUG

Anidulafungin, VER002

Trial Locations (1)

19406

Versicor, Inc., King of Prussia

Sponsors

Lead Sponsor

Collaborators (1)

Vicuron Pharmaceuticals

All Listed Sponsors

collaborator

Vicuron Pharmaceuticals

INDUSTRY

lead

Pfizer

INDUSTRY